Immunotherapies  ||| S:0 E:16 ||| NNP
and  ||| S:16 E:20 ||| CC
novel  ||| S:20 E:26 ||| NN
combinations ||| S:26 E:38 ||| NNS
:  ||| S:38 E:40 ||| :
the  ||| S:40 E:44 ||| DT
focus  ||| S:44 E:50 ||| NN
of  ||| S:50 E:53 ||| IN
advances  ||| S:53 E:62 ||| NNS
in  ||| S:62 E:65 ||| IN
the  ||| S:65 E:69 ||| DT
treatment  ||| S:69 E:79 ||| NN
of  ||| S:79 E:82 ||| IN
melanoma  ||| S:82 E:91 ||| NN
Since  ||| S:91 E:97 ||| IN
2011 ||| S:97 E:101 ||| CD
,  ||| S:101 E:103 ||| ,
the  ||| S:103 E:107 ||| DT
approval  ||| S:107 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
four  ||| S:119 E:124 ||| CD
different  ||| S:124 E:134 ||| JJ
classes  ||| S:134 E:142 ||| NNS
of  ||| S:142 E:145 ||| IN
novel  ||| S:145 E:151 ||| NN
drugs  ||| S:151 E:157 ||| NNS
( ||| S:157 E:158 ||| -LRB-
the  ||| S:158 E:162 ||| DT
anti-CTLA-4  ||| S:162 E:174 ||| JJ
agent ||| S:174 E:179 ||| NN
,  ||| S:179 E:181 ||| ,
ipilimumab ||| S:181 E:191 ||| NNS
;  ||| S:191 E:193 ||| :
BRAF  ||| S:193 E:198 ||| NNP
inhibitors  ||| S:198 E:209 ||| NNS
[ ||| S:209 E:210 ||| -LRB-
BRAFi ||| S:210 E:215 ||| NNP
] ||| S:215 E:216 ||| -RRB-
;  ||| S:216 E:218 ||| :
MEK  ||| S:218 E:222 ||| NNP
inhibitors  ||| S:222 E:233 ||| NNS
[ ||| S:233 E:234 ||| -LRB-
MEKi ||| S:234 E:238 ||| NNP
] ||| S:238 E:239 ||| -RRB-
;  ||| S:239 E:241 ||| :
and  ||| S:241 E:245 ||| CC
the  ||| S:245 E:249 ||| DT
anti-PD-1  ||| S:249 E:259 ||| JJ
drug ||| S:259 E:263 ||| NN
,  ||| S:263 E:265 ||| ,
pembrolizumab ||| S:265 E:278 ||| CD
)  ||| S:278 E:280 ||| -RRB-
has  ||| S:280 E:284 ||| VBZ
revolutionized  ||| S:284 E:299 ||| VBG
the  ||| S:299 E:303 ||| DT
care  ||| S:303 E:308 ||| NN
of  ||| S:308 E:311 ||| IN
advanced  ||| S:311 E:320 ||| JJ
melanoma ||| S:320 E:328 ||| NN
,  ||| S:328 E:330 ||| ,
with  ||| S:330 E:335 ||| IN
the  ||| S:335 E:339 ||| DT
disease  ||| S:339 E:347 ||| NN
becoming  ||| S:347 E:356 ||| VBG
a  ||| S:356 E:358 ||| DT
model  ||| S:358 E:364 ||| NN
for  ||| S:364 E:368 ||| IN
the  ||| S:368 E:372 ||| DT
development  ||| S:372 E:384 ||| NN
of  ||| S:384 E:387 ||| IN
new  ||| S:387 E:391 ||| JJ
treatments  ||| S:391 E:402 ||| NNS
for  ||| S:402 E:406 ||| IN
other  ||| S:406 E:412 ||| JJ
types  ||| S:412 E:418 ||| NNS
of  ||| S:418 E:421 ||| IN
cancer ||| S:421 E:427 ||| NN
.  ||| S:427 E:429 ||| .
Further  ||| S:429 E:437 ||| JJ
advances  ||| S:437 E:446 ||| NNS
in  ||| S:446 E:449 ||| IN
the  ||| S:449 E:453 ||| DT
treatment  ||| S:453 E:463 ||| NN
of  ||| S:463 E:466 ||| IN
melanoma  ||| S:466 E:475 ||| NN
represented  ||| S:475 E:487 ||| VBD
some  ||| S:487 E:492 ||| DT
of  ||| S:492 E:495 ||| IN
the  ||| S:495 E:499 ||| DT
key  ||| S:499 E:503 ||| JJ
highlights  ||| S:503 E:514 ||| NN
of  ||| S:514 E:517 ||| IN
the  ||| S:517 E:521 ||| DT
European  ||| S:521 E:530 ||| NNP
Society  ||| S:530 E:538 ||| NNP
of  ||| S:538 E:541 ||| IN
Medical  ||| S:541 E:549 ||| NNP
Oncology  ||| S:549 E:558 ||| NNP
( ||| S:558 E:559 ||| -LRB-
ESMO ||| S:559 E:563 ||| NNP
)  ||| S:563 E:565 ||| -RRB-
2014  ||| S:565 E:570 ||| CD
congress ||| S:570 E:578 ||| NN
.  ||| S:578 E:580 ||| .
The  ||| S:580 E:584 ||| DT
first  ||| S:584 E:590 ||| JJ
phase  ||| S:590 E:596 ||| NN
III  ||| S:596 E:600 ||| NNP
trial  ||| S:600 E:606 ||| NN
of  ||| S:606 E:609 ||| IN
an  ||| S:609 E:612 ||| DT
anti-PD-1  ||| S:612 E:622 ||| JJ
agent  ||| S:622 E:628 ||| NN
to  ||| S:628 E:631 ||| TO
report  ||| S:631 E:638 ||| VB
the  ||| S:638 E:642 ||| DT
CA209-037  ||| S:642 E:652 ||| JJ
study  ||| S:652 E:658 ||| NN
included  ||| S:658 E:667 ||| VBD
405  ||| S:667 E:671 ||| CD
patients  ||| S:671 E:680 ||| NNS
with  ||| S:680 E:685 ||| IN
metastatic  ||| S:685 E:696 ||| JJ
melanoma  ||| S:696 E:705 ||| NNS
previously  ||| S:705 E:716 ||| RB
treated  ||| S:716 E:724 ||| VBN
with  ||| S:724 E:729 ||| IN
ipilimumab  ||| S:729 E:740 ||| NNS
who  ||| S:740 E:744 ||| WP
were  ||| S:744 E:749 ||| VBD
randomized  ||| S:749 E:760 ||| CD
2 ||| S:760 E:761 ||| CD
: ||| S:761 E:762 ||| :
1  ||| S:762 E:764 ||| CD
to  ||| S:764 E:767 ||| TO
receive  ||| S:767 E:775 ||| VB
nivolumab  ||| S:775 E:785 ||| CD
3  ||| S:785 E:787 ||| CD
mg ||| S:787 E:789 ||| CD
/ ||| S:789 E:790 ||| CD
kg  ||| S:790 E:793 ||| CD
every  ||| S:793 E:799 ||| DT
2  ||| S:799 E:801 ||| CD
weeks  ||| S:801 E:807 ||| NNS
or  ||| S:807 E:810 ||| CC
investigator ||| S:810 E:822 ||| NN
's  ||| S:822 E:825 ||| POS
choice  ||| S:825 E:832 ||| NN
chemotherapy ||| S:832 E:844 ||| NN
.  ||| S:844 E:846 ||| .
Nivolumab  ||| S:846 E:856 ||| NNP
was  ||| S:856 E:860 ||| VBD
associated  ||| S:860 E:871 ||| VBN
with  ||| S:871 E:876 ||| IN
a  ||| S:876 E:878 ||| DT
higher  ||| S:878 E:885 ||| JJR
response  ||| S:885 E:894 ||| NN
rate  ||| S:894 E:899 ||| NN
than  ||| S:899 E:904 ||| IN
chemotherapy  ||| S:904 E:917 ||| NN
and  ||| S:917 E:921 ||| CC
was  ||| S:921 E:925 ||| VBD
well  ||| S:925 E:930 ||| RB
tolerated ||| S:930 E:939 ||| JJ
,  ||| S:939 E:941 ||| ,
with  ||| S:941 E:946 ||| IN
adverse  ||| S:946 E:954 ||| JJ
events  ||| S:954 E:961 ||| NNS
mostly  ||| S:961 E:968 ||| RB
low  ||| S:968 E:972 ||| JJ
grade  ||| S:972 E:978 ||| NN
and  ||| S:978 E:982 ||| CC
manageable  ||| S:982 E:993 ||| JJ
using  ||| S:993 E:999 ||| VBG
recommended  ||| S:999 E:1011 ||| JJ
treatment  ||| S:1011 E:1021 ||| NN
algorithms ||| S:1021 E:1031 ||| NN
.  ||| S:1031 E:1033 ||| .
New  ||| S:1033 E:1037 ||| JJ
data  ||| S:1037 E:1042 ||| NNS
on  ||| S:1042 E:1045 ||| IN
other  ||| S:1045 E:1051 ||| JJ
immunotherapies ||| S:1051 E:1066 ||| NN
,  ||| S:1066 E:1068 ||| ,
namely  ||| S:1068 E:1075 ||| RB
ipilimumab  ||| S:1075 E:1086 ||| JJ
and  ||| S:1086 E:1090 ||| CC
pembrolizumab ||| S:1090 E:1103 ||| NN
,  ||| S:1103 E:1105 ||| ,
were  ||| S:1105 E:1110 ||| VBD
also  ||| S:1110 E:1115 ||| RB
reported ||| S:1115 E:1123 ||| VBD
.  ||| S:1123 E:1125 ||| .
In  ||| S:1125 E:1128 ||| IN
addition ||| S:1128 E:1136 ||| NN
,  ||| S:1136 E:1138 ||| ,
outside  ||| S:1138 E:1146 ||| JJ
of  ||| S:1146 E:1149 ||| IN
immunotherapy ||| S:1149 E:1162 ||| NN
,  ||| S:1162 E:1164 ||| ,
combination  ||| S:1164 E:1176 ||| NN
approaches  ||| S:1176 E:1187 ||| VBZ
involving  ||| S:1187 E:1197 ||| VBG
targeted  ||| S:1197 E:1206 ||| VBN
agents  ||| S:1206 E:1213 ||| NNS
were  ||| S:1213 E:1218 ||| VBD
also  ||| S:1218 E:1223 ||| RB
a  ||| S:1223 E:1225 ||| DT
major  ||| S:1225 E:1231 ||| JJ
focus  ||| S:1231 E:1237 ||| NN
of  ||| S:1237 E:1240 ||| IN
ESMO  ||| S:1240 E:1245 ||| NNP
this  ||| S:1245 E:1250 ||| DT
year ||| S:1250 E:1254 ||| NN
,  ||| S:1254 E:1256 ||| ,
with  ||| S:1256 E:1261 ||| IN
two  ||| S:1261 E:1265 ||| CD
major  ||| S:1265 E:1271 ||| JJ
phase  ||| S:1271 E:1277 ||| NN
III  ||| S:1277 E:1281 ||| NNP
studies  ||| S:1281 E:1289 ||| NNS
of  ||| S:1289 E:1292 ||| IN
combined  ||| S:1292 E:1301 ||| JJ
BRAF  ||| S:1301 E:1306 ||| NNP
inhibition  ||| S:1306 E:1317 ||| NN
and  ||| S:1317 E:1321 ||| CC
MEK  ||| S:1321 E:1325 ||| NNP
inhibition  ||| S:1325 E:1336 ||| VBZ
being  ||| S:1336 E:1342 ||| VBG
reported ||| S:1342 E:1350 ||| VBN
.  ||| S:1350 E:1352 ||| .
Overall ||| S:1352 E:1359 ||| RB
,  ||| S:1359 E:1361 ||| ,
new  ||| S:1361 E:1365 ||| JJ
clinical  ||| S:1365 E:1374 ||| JJ
trial  ||| S:1374 E:1380 ||| NN
findings  ||| S:1380 E:1389 ||| NNS
reported  ||| S:1389 E:1398 ||| VBD
at  ||| S:1398 E:1401 ||| IN
ESMO  ||| S:1401 E:1406 ||| NNP
further  ||| S:1406 E:1414 ||| RB
endorse  ||| S:1414 E:1422 ||| VB
the  ||| S:1422 E:1426 ||| DT
view  ||| S:1426 E:1431 ||| NN
that  ||| S:1431 E:1436 ||| IN
melanoma ||| S:1436 E:1444 ||| NN
,  ||| S:1444 E:1446 ||| ,
given  ||| S:1446 E:1452 ||| VBN
the  ||| S:1452 E:1456 ||| DT
continued  ||| S:1456 E:1466 ||| JJ
development  ||| S:1466 E:1478 ||| NN
of  ||| S:1478 E:1481 ||| IN
novel ||| S:1481 E:1486 ||| NN
,  ||| S:1486 E:1488 ||| ,
effective  ||| S:1488 E:1498 ||| JJ
compounds ||| S:1498 E:1507 ||| NN
,  ||| S:1507 E:1509 ||| ,
can  ||| S:1509 E:1513 ||| MD
accurately  ||| S:1513 E:1524 ||| RB
be  ||| S:1524 E:1527 ||| VB
described  ||| S:1527 E:1537 ||| VBN
as  ||| S:1537 E:1540 ||| IN
the  ||| S:1540 E:1544 ||| DT
most  ||| S:1544 E:1549 ||| RBS
dynamic  ||| S:1549 E:1557 ||| JJ
field  ||| S:1557 E:1563 ||| NN
of  ||| S:1563 E:1566 ||| IN
oncology  ||| S:1566 E:1575 ||| NN
at  ||| S:1575 E:1578 ||| IN
present ||| S:1578 E:1585 ||| JJ
.  ||| S:1585 E:1587 ||| .
